Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of brentuximab vedotin in relapsed or refractory EBV- and CD30-positive lymphomas
KCT0009738Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), plasmablastic lymphoma (PBL), lymphomatoid granulomatosis (LYG), sponsored by Millennium Pharmaceuticals. Started Mar 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)plasmablastic lymphoma (PBL)lymphomatoid granulomatosis (LYG)
Beyond the preview
Go deeper on KCT0009738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009738.